GERD
Conditions
Brief summary
Background: Gastroesophageal reflux disease (GERD), which affects at least 20% of adult Americans, may be especially common and severe in Veteran patients. Proton pump inhibitors (PPIs), which block gastric acid production, are the most effective medications for GERD, and the VA spends more than $177 million each year on outpatient PPI prescriptions. PPIs do not prevent the reflux of non-acidic material and do not completely eliminate esophageal acid exposure, however, and bothersome GERD symptoms persist in approximately 40% of patients treated with PPIs. Recent studies using the new technique of esophageal pH/ impedance monitoring, which detects the reflux of both acidic and non-acidic materials, have shown that PPI-resistant GERD symptoms correlate with episodes of reflux (acidic and/or non-acidic) in approximately one-half of patients. For those patients, an antireflux operation might relieve symptoms and obviate the expense of ineffective PPI therapy, but the efficacy of modern, laparoscopic fundoplication in this regard is not clear. For patients with PPI-resistant GERD symptoms, furthermore, the efficacy of medications that that can prevent gastroesophageal reflux (e.g. baclofen) or diminish pain of esophageal origin (e.g. neurotropic agents like desipramine) also is not clear. Study Hypothesis: Laparoscopic antireflux surgery (Nissen fundoplication) is superior to medical therapy (PPIs plus baclofen and desipramine) for GERD patients who, while on PPIs, have persistent episodes of heartburn that are associated with reflux episodes or with abnormal esophageal acid exposure by esophageal pH/impedance monitoring. Study Goals: The primary goal is to compare the efficacy of laparoscopic Nissen fundoplication and medical therapy (PPIs plus baclofen and desipramine) for GERD patients who, while on PPIs, have persistent episodes of heartburn that are associated with reflux episodes or with abnormal esophageal acid exposure by esophageal pH/impedance monitoring, and to compare the efficacy of each therapy with placebo. Secondary goals are: 1) To determine the frequency with which non-GERD disorders underlie PPI failure, 2) To determine the frequency of functional gastrointestinal symptoms, anxiety and depression in patients who have persistent heartburn while on PPIs, 3) To determine whether functional gastrointestinal symptoms, anxiety and depression is associated with the outcomes of medical and surgical therapies, and 4) To determine whether the outcome of Nissen fundoplication is associated with adherence to technical aspects of the operation. Study Design: Up to 16 VA medical centers, there will be a 30-month recruitment period to enroll 108 patients with heartburn that is refractory to PPI therapy. Patients will have their baseline GERD symptoms scored using the GERD Health-Related Quality of Life (GERD-HRQL) index, and will have endoscopy, esophageal manometry and esophageal pH/impedance monitoring while on PPI therapy. Patients who have episodes of heartburn that are associated with reflux episodes or with abnormal esophageal acid exposure by esophageal pH/impedance monitoring will be randomized to one of three treatment groups: Surgical Treatment (laparoscopic Nissen fundoplication), Active Medical Treatment (omeprazole and baclofen initially; desipramine for baclofen failures) or Placebo Medical Treatment (omeprazole, placebo baclofen, placebo desipramine). All patients will have quarterly clinic visits for symptom scoring and laboratory testing. At one year, patients will have a final symptom scoring and repeat endoscopy, esophageal manometry and esophageal pH/impedance monitoring. Treatment success will be defined as 50% improvement in the GERD-HRQL score at 12 months. Patients also will complete the Hospital Anxiety and Depression Scale (HADS), Rome III Functional GI Disorders Questionnaire and the Short-Form Health Survey (SF-36) at baseline and one year. The results will be correlated with treatment outcomes.
Interventions
DEVICENissen fundoplication
laparoscopic antireflux surgery
DRUGbaclofen
Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals. The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved.
DRUGDesipramine
Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
Sponsors
VA Office of Research and Development
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Partial Double Blind (Medical Treatment Groups)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-70 years * History of heartburn (defined as a burning sensation in the retrosternal area of the chest) that is refractory to antisecretory medications * Initial GERD-HRQL: * Total score must be at least 6 and at least one of the six heartburn questions must be scored at least 2 * GERD-HRQL after two weeks of treatment with omeprazole: * Total score must be \>50% of the initial GERD-HRQL score and at least one of the six heartburn questions must be scored at least 2 * Either or both of the following by baseline esophageal pH/multichannel intraluminal impedance (MII) monitoring in patients on omeprazole 20 mg two times a day (BID): * Positive symptom association probability (SAP) (\>95%) for acid reflux, non-acid reflux or all reflux. * Abnormal acid reflux (esophageal pH\<4 for at least 4.2% of the 24-hour monitoring period)
Exclusion criteria
* Patients who do not have heartburn, defined as a burning sensation in the chest * Patients unwilling or unable to provide informed consent * Pregnancy or women unwilling to use effective contraception * Age \<18 or \>70 years * History of surgery on the stomach or esophagus * History of seizure disorder * History of heart block * Allergy to or previous inability to tolerate study medications (omeprazole, baclofen, desipramine) * Esophageal varices * Cirrhosis * Co-morbidity of sufficient severity to preclude elective surgery (e.g. pulmonary, cardiac, renal, liver disease) * History of disorders that can cause medically-refractory GERD symptoms (eosinophilic esophagitis, neoplasms of the upper gastrointestinal tract, gastroparesis, achalasia) * Myocardial infarction within the past 6 months * History of schizophrenia * Current use of clopidogrel * Patients who have a contraindication to omeprazole or baclofen or who require therapy with a medication that has a clinically important drug interaction with omeprazole or baclofen. * Patients who, in the judgment of the PI, are not suitable candidates for therapy with a study medication (omeprazole, baclofen, desipramine) * Initial GERD-HRQL score: Total score \<6 and/or all heartburn scores \<2 * Inability to tolerate omeprazole during the 2-week treatment phase (before randomization) * GERD-HRQL after two weeks of treatment with omeprazole: Total score less than or equal to 50% of initial GERD-HRQL score and/or all heartburn scores \<2 * Laboratory abnormalities including: * Platelet count \<100,000 * international normalized ratio (INR) \>1.5 (off anticoagulants) * Serum creatinine \>2.0 mg per deciliter * Endoscopic abnormalities including: * Los Angeles Classification of Oesophagitis (LA grade) C or D reflux esophagitis * Active ulceration of the esophagus that is not due to reflux esophagitis * Candida esophagitis * Esophageal varices * Active ulceration of the stomach and/or duodenum * Neoplasm of the esophagus, stomach or duodenum * Gastric outlet obstruction * Eosinophilic esophagitis at least (15 eosinophils per high power field in any esophageal biopsy specimen) * Manometric abnormalities including: * Achalasia * Complete aperistalsis * Negative SAP ( 95%) for acid reflux, non-acid reflux and all reflux on baseline combined esophageal pH/MII monitoring and normal acid reflux (esophageal pH\<4 for \<4.2% of the 24-hour monitoring period) * Study surgeon identifies a contraindication to laparoscopic Nissen fundoplication * Morbid obesity (BMI at least 40) * Large paraesophageal hernia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months | 12 months | Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months. Failure; \<50% improvement in the baseline GERD-HRQL score at 12 months or: 1. For patients randomized to Surgical Treatment: a.\<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit. 2. For patients randomized to Active Medical or Placebo Medical Treatment: a.inability to tolerate both study medications or b.For patients treated with desipramine, i.\<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.\<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Enrolled Participants With Reflux Esophagus. | Screening | — |
| Number of Enrolled Participants With Eosinophilic Esophagitis | Screening | — |
| Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum. | Screening | — |
| Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum | Screening | — |
| Number of Enrolled Participants With Candida Esophagitis. | Screening | — |
| Number of Enrolled Participants With Gastric Outlet Obstruction | Screening | — |
| Number of Enrolled Participants With Achalasia | Screening | — |
| Number of Enrolled Participants With Aperistalsis | Screening | — |
| Number of Enrolled Participants With Distal Esophageal Spasm | Screening | — |
| Number of Enrolled Participants With Nutcracker Esophagus | Screening | — |
| Number of Enrolled Participants With Ineffective Esophageal Motility | Screening | — |
| Number of Enrolled Participants With Rapid Contraction | Screening | — |
| Number of Enrolled Participants With Hypertensive Peristalsis | Screening | — |
| Number of Enrolled Participants With Jackhammer Esophagus | Screening | — |
| Number of Enrolled Participants With Weak Peristalsis I | Screening | — |
| Number of Enrolled Participants With Weak Peristalsis II | Screening | — |
| Number of Enrolled Participants With Anxiety and/or Depression | Screening | — |
| Number of Enrolled Participants With Functional Heartburn | Screening | — |
| Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin | Screening | — |
| Number of Enrolled Participants With Functional Dysphagia | Screening | — |
| Number of Enrolled Participants With Globus | Screening | — |
| Number of Enrolled Participants With Belching Disorders | Screening | — |
| Number of Enrolled Participants With Chronic Idiopathic Nausea | Screening | — |
| Number of Enrolled Participants With Functional Vomiting | Screening | — |
| Number of Enrolled Participants With Cyclic Vomiting Syndrome | Screening | — |
| Number of Enrolled Participants With Irritable Bowel Syndrome | Screening | — |
| Number of Enrolled Participants With Functional Bloating | Screening | — |
| Number of Enrolled Participants With Functional Diarrhea | Screening | — |
| Number of Enrolled Participants With Unspecified Functional Bowel Disorder | Screening | — |
| Number of Enrolled Participants With Functional Gallbladder Disorder | Screening | — |
| Number of Successful Participants With Anxiety and/or Depression. | 12 months | Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. |
| Number of Successful Participants With Functional Heartburn | 12 months | Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin | 12 months | Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Functional Dysphagia | 12 months | Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Globus | 12 months | Presence of globus as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Belching Disorders | 12 months | Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Chronic Idiopathic Nausea | 12 months | Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Functional Vomiting | 12 months | Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Cyclic Vomiting Syndrome | 12 months | Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Irritable Bowel Syndrome | 12 months | Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Functional Bloating | 12 months | Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Functional Diarrhea | 12 months | Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Unspecified Functional Bowel Disorder | 12 months | Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Participants With Functional Gallbladder Disorder | 12 months | Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. |
| Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed. | 12 months | — |
| Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed. | 12 months | — |
| Number of Enrolled Participants With Esophageal Ulceration. | Screening | — |
| Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed. | 12 months | — |
| Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed. | 12 months | — |
| Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed. | 12 months | — |
| Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed. | 12 months | — |
| Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed. | 12 months | — |
| Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed. | 12 months | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Medical Treatment Group baclofen: Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.
The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved.
Desipramine: Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit. | 25 |
| Surgical Treatment Group Nissen fundoplication: laparoscopic antireflux surgery | 27 |
| Placebo Medical Treatment Group baclofen: Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.
The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved.
Desipramine: Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit. | 26 |
| Not Randomized Subset of all enrolled participants who did not end up being randomized to the study. | 288 |
| Total | 366 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Pre Randomization | Functional heartburn | 0 | 0 | 0 | 99 |
| Pre Randomization | GERD, PPI-Responsive | 0 | 0 | 0 | 42 |
| Pre Randomization | Non-GERD organic disorders | 0 | 0 | 0 | 23 |
| Pre Randomization | Technical Exclusions | 0 | 0 | 0 | 54 |
| Pre Randomization | Withdrawal by Subject | 0 | 0 | 0 | 70 |
Baseline characteristics
| Characteristic | Medical Treatment Group | Surgical Treatment Group | Placebo Medical Treatment Group | Not Randomized | Total |
|---|---|---|---|---|---|
| Age, Continuous | 43.9 years STANDARD_DEVIATION 12.2 | 44.9 years STANDARD_DEVIATION 11.8 | 47.2 years STANDARD_DEVIATION 11.7 | 49.3 years STANDARD_DEVIATION 12.2 | 45.4 years STANDARD_DEVIATION 11.8 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 7 Participants | 2 Participants | 40 Participants | 53 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 21 Participants | 20 Participants | 23 Participants | 230 Participants | 294 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 9 Participants | 10 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 3 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 2 Participants | 5 Participants | 54 Participants | 63 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 2 Participants | 2 Participants | 16 Participants | 22 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 6 Participants | 1 Participants | 21 Participants | 29 Participants |
| Race (NIH/OMB) White | 20 Participants | 17 Participants | 17 Participants | 183 Participants | 237 Participants |
| Sex: Female, Male Female | 7 Participants | 4 Participants | 3 Participants | 63 Participants | 77 Participants |
| Sex: Female, Male Male | 18 Participants | 23 Participants | 23 Participants | 216 Participants | 280 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 25 | 0 / 27 | 0 / 26 | 0 / 288 |
| other Total, other adverse events | 18 / 25 | 17 / 27 | 18 / 26 | 79 / 366 |
| serious Total, serious adverse events | 4 / 25 | 4 / 27 | 3 / 26 | 15 / 366 |
Outcome results
Primary
Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months
Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months. Failure; \<50% improvement in the baseline GERD-HRQL score at 12 months or: 1. For patients randomized to Surgical Treatment: a.\<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit. 2. For patients randomized to Active Medical or Placebo Medical Treatment: a.inability to tolerate both study medications or b.For patients treated with desipramine, i.\<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.\<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit.
Time frame: 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months | 7 Participants |
| Surgical Treatment Group | Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months | 18 Participants |
| Placebo Medical Treatment Group | Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months | 3 Participants |
Secondary
Number of Enrolled Participants With Achalasia
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for achalasia
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Achalasia | 2 Participants |
Secondary
Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for active ulcerations of the stomach and/or duodenum
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum. | 3 Participants |
Secondary
Number of Enrolled Participants With Anxiety and/or Depression
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for anxiety and/or depression
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Anxiety and/or Depression | 125 Participants |
Secondary
Number of Enrolled Participants With Aperistalsis
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for aperistalsis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Aperistalsis | 0 Participants |
Secondary
Number of Enrolled Participants With Belching Disorders
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for belching disorders
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Belching Disorders | 130 Participants |
Secondary
Number of Enrolled Participants With Candida Esophagitis.
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for candida esophagitis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Candida Esophagitis. | 3 Participants |
Secondary
Number of Enrolled Participants With Chronic Idiopathic Nausea
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for chronic idiopathic nausea
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Chronic Idiopathic Nausea | 51 Participants |
Secondary
Number of Enrolled Participants With Cyclic Vomiting Syndrome
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for cyclic vomiting syndrome
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Cyclic Vomiting Syndrome | 86 Participants |
Secondary
Number of Enrolled Participants With Distal Esophageal Spasm
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for distal esophageal spasm
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Distal Esophageal Spasm | 3 Participants |
Secondary
Number of Enrolled Participants With Eosinophilic Esophagitis
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for eosinophilic esophagitis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Eosinophilic Esophagitis | 16 Participants |
Secondary
Number of Enrolled Participants With Esophageal Ulceration.
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for esophageal ulceration.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Esophageal Ulceration. | 0 Participants |
Secondary
Number of Enrolled Participants With Functional Bloating
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for functional bloating
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Functional Bloating | 8 Participants |
Secondary
Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for functional chest pain of presumed esophageal origin
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin | 13 Participants |
Secondary
Number of Enrolled Participants With Functional Diarrhea
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for functional diarrhea
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Functional Diarrhea | 4 Participants |
Secondary
Number of Enrolled Participants With Functional Dysphagia
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for functional dysphagia
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Functional Dysphagia | 7 Participants |
Secondary
Number of Enrolled Participants With Functional Gallbladder Disorder
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for functional gallbladder disorder
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Functional Gallbladder Disorder | 1 Participants |
Secondary
Number of Enrolled Participants With Functional Heartburn
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for functional heartburn
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Functional Heartburn | 221 Participants |
Secondary
Number of Enrolled Participants With Functional Vomiting
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for functional vomiting
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Functional Vomiting | 32 Participants |
Secondary
Number of Enrolled Participants With Gastric Outlet Obstruction
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for gastric outlet obstruction
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Gastric Outlet Obstruction | 0 Participants |
Secondary
Number of Enrolled Participants With Globus
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for globus
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Globus | 0 Participants |
Secondary
Number of Enrolled Participants With Hypertensive Peristalsis
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for hypertensive peristalsis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Hypertensive Peristalsis | 3 Participants |
Secondary
Number of Enrolled Participants With Ineffective Esophageal Motility
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for ineffective esophageal motility
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Ineffective Esophageal Motility | 1 Participants |
Secondary
Number of Enrolled Participants With Irritable Bowel Syndrome
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for irritable bowel syndrome
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Irritable Bowel Syndrome | 152 Participants |
Secondary
Number of Enrolled Participants With Jackhammer Esophagus
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for jackhammer esophagus
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Jackhammer Esophagus | 8 Participants |
Secondary
Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for neoplasm of the esophagus, stomach or duodenum
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum | 0 Participants |
Secondary
Number of Enrolled Participants With Nutcracker Esophagus
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for nutcracker esophagus
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Nutcracker Esophagus | 2 Participants |
Secondary
Number of Enrolled Participants With Rapid Contraction
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for rapid contraction
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Rapid Contraction | 2 Participants |
Secondary
Number of Enrolled Participants With Reflux Esophagus.
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for reflux esophagus.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Reflux Esophagus. | 4 Participants |
Secondary
Number of Enrolled Participants With Unspecified Functional Bowel Disorder
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for unspecified functional bowel disorder
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Unspecified Functional Bowel Disorder | 56 Participants |
Secondary
Number of Enrolled Participants With Weak Peristalsis I
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for weak peristalsis I
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Weak Peristalsis I | 10 Participants |
Secondary
Number of Enrolled Participants With Weak Peristalsis II
Time frame: Screening
Population: The Overall number of participants analyzed represents those Enrolled Participants who were evaluated for weak peristalsis II
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Enrolled Participants With Weak Peristalsis II | 9 Participants |
Secondary
Number of Successful Participants With Anxiety and/or Depression.
Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Anxiety and/or Depression. | 2 Participants |
| Surgical Treatment Group | Number of Successful Participants With Anxiety and/or Depression. | 5 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Anxiety and/or Depression. | 0 Participants |
Secondary
Number of Successful Participants With Belching Disorders
Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Belching Disorders | 3 Participants |
| Surgical Treatment Group | Number of Successful Participants With Belching Disorders | 12 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Belching Disorders | 2 Participants |
Secondary
Number of Successful Participants With Chronic Idiopathic Nausea
Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Chronic Idiopathic Nausea | 0 Participants |
| Surgical Treatment Group | Number of Successful Participants With Chronic Idiopathic Nausea | 3 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Chronic Idiopathic Nausea | 0 Participants |
Secondary
Number of Successful Participants With Cyclic Vomiting Syndrome
Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Cyclic Vomiting Syndrome | 1 Participants |
| Surgical Treatment Group | Number of Successful Participants With Cyclic Vomiting Syndrome | 7 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Cyclic Vomiting Syndrome | 1 Participants |
Secondary
Number of Successful Participants With Functional Bloating
Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Functional Bloating | 1 Participants |
| Surgical Treatment Group | Number of Successful Participants With Functional Bloating | 1 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Functional Bloating | 0 Participants |
Secondary
Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin
Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin | 0 Participants |
| Surgical Treatment Group | Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin | 0 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin | 0 Participants |
Secondary
Number of Successful Participants With Functional Diarrhea
Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Functional Diarrhea | 0 Participants |
| Surgical Treatment Group | Number of Successful Participants With Functional Diarrhea | 0 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Functional Diarrhea | 0 Participants |
Secondary
Number of Successful Participants With Functional Dysphagia
Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Functional Dysphagia | 0 Participants |
| Surgical Treatment Group | Number of Successful Participants With Functional Dysphagia | 0 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Functional Dysphagia | 0 Participants |
Secondary
Number of Successful Participants With Functional Gallbladder Disorder
Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Functional Gallbladder Disorder | 0 Participants |
| Surgical Treatment Group | Number of Successful Participants With Functional Gallbladder Disorder | 0 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Functional Gallbladder Disorder | 0 Participants |
Secondary
Number of Successful Participants With Functional Heartburn
Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Functional Heartburn | 7 Participants |
| Surgical Treatment Group | Number of Successful Participants With Functional Heartburn | 14 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Functional Heartburn | 3 Participants |
Secondary
Number of Successful Participants With Functional Vomiting
Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Functional Vomiting | 1 Participants |
| Surgical Treatment Group | Number of Successful Participants With Functional Vomiting | 1 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Functional Vomiting | 1 Participants |
Secondary
Number of Successful Participants With Globus
Presence of globus as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Globus | 0 Participants |
| Surgical Treatment Group | Number of Successful Participants With Globus | 0 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Globus | 0 Participants |
Secondary
Number of Successful Participants With Irritable Bowel Syndrome
Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Irritable Bowel Syndrome | 3 Participants |
| Surgical Treatment Group | Number of Successful Participants With Irritable Bowel Syndrome | 10 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Irritable Bowel Syndrome | 3 Participants |
Secondary
Number of Successful Participants With Unspecified Functional Bowel Disorder
Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire.
Time frame: 12 months
Population: Number of treatment successes.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Participants With Unspecified Functional Bowel Disorder | 2 Participants |
| Surgical Treatment Group | Number of Successful Participants With Unspecified Functional Bowel Disorder | 5 Participants |
| Placebo Medical Treatment Group | Number of Successful Participants With Unspecified Functional Bowel Disorder | 0 Participants |
Secondary
Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.
Time frame: 12 months
Population: Surgical participants with at least 50% improvement in the baseline GERD-HRQL score at 12 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed. | 14 Participants |
Secondary
Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.
Time frame: 12 months
Population: Surgical participants with at least 50% improvement in the baseline GERD-HRQL score at 12 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed. | 18 Participants |
Secondary
Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.
Time frame: 12 months
Population: Surgical participants with at least 50% improvement in the baseline GERD-HRQL score at 12 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed. | 18 Participants |
Secondary
Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.
Time frame: 12 months
Population: Surgical participants with at least 50% improvement in the baseline GERD-HRQL score at 12 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed. | 18 Participants |
Secondary
Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.
Time frame: 12 months
Population: Surgical participants with at least 50% improvement in the baseline GERD-HRQL score at 12 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed. | 15 Participants |
Secondary
Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.
Time frame: 12 months
Population: Surgical participants with at least 50% improvement in the baseline GERD-HRQL score at 12 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed. | 18 Participants |
Secondary
Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.
Time frame: 12 months
Population: Surgical participants with at least 50% improvement in the baseline GERD-HRQL score at 12 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed. | 18 Participants |
Secondary
Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.
Time frame: 12 months
Population: Surgical participants with at least 50% improvement in the baseline GERD-HRQL score at 12 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Medical Treatment Group | Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed. | 14 Participants |